A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A Multicentre Prospective Controlled Observer Blinded Cohort Study in Patients With Acromegaly to Evaluate the Risk of Cardiac Valvular Regurgitation in Patients Treated With Lanreotide Relative to Patients Treated With Octreotide
Study Start Date :
Actual Primary Completion Date :
February 18, 2005
Actual Study Completion Date :
February 18, 2005
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patient has a diagnosis of Acromegaly
Patient is being treated with lanreotide or octreotide in any dose form at the selection visit or is a de novo patient who is due to commence treatment within 2 weeks of baseline
Patient started treatment with either lanreotide or octreotide when both products were available on the market in their country
Patient must not change treatment form lanreotide to octreotide or vice versa for the duration of the study
Patients with known significant valve abnormalities prior to treatment with either lanreotide or octreotide
Patients who have received treatment with a somatostatin analogue other than lanreotide or octreotide for more than 3 months
Patients who have received treatment with a GH antagonist for more than 3 months
Patients who have had heart valve replacement therapy